On TRAC with charity donations
Cornish Regulatory Affairs Specialist raises £20,000 through volunteer project
The Camborne, UK-based company, which works with pharmaceutical manufacturers around the world, has donated £22,000 since launching a pioneering project in 2006 in which volunteers across Cornwall raised funds for a charity or community group in return for a 30-minute question and answer session.
The project was launched four years ago to enable pharmaceutical companies to get feedback on Patient Information Leaflets from members of the public, and gave everyone taking part the opportunity to raise money by donating £20 to a nominated charity or group.
More than 50 community groups such as Cornwall Blind Association, St Agnes Football Club, Truro Fencing Club, Cornwall Air Ambulance, and Camborne Bowling Association have all had their funds boosted by the volunteer scheme.
TRAC Director Sarah Trethowan said: ‘When we came up with the idea of running the volunteer project we really didn’t know if it would take off, but are absolutely thrilled that we have been able to donate £22,000 to good causes and community projects in Cornwall.
‘The beauty of the volunteer project was that not only did every person taking part in it raise £20 towards their nominated cause but by taking part they were also helping to improve the way pharmaceutical companies produce information leaflets, making them clearer and easier to understand.’
With the project now coming to an end, TRAC is continuing its charity work by becoming a member of Cornwall Community Foundation’s 100 Club, which has been launched to enable businesses in the county to help fund grassroots organisations and projects.
TRAC recently became the second firm in Cornwall to achieve a Silver Investors in People (IIP) standard. It also took top honours in the Graduate Development Category at the Cornwall Excellence in Business Training Awards 2010.
You may also like
Regulatory
Immusoft receives FDA Fast Track Designation for ISP-001, a first-in-class engineered B cell therapy for MPS I
Immusoft’s ISP-001, designed to deliver continuous enzyme production through engineered B cells, becomes the first clinical-stage therapy of its kind to receive FDA Fast Track designation
Regulatory
MoonLake Immunotherapeutics faces Securities Class Action after disastrous Phase III trial results
The announcement about the trial results for the product candidate sonelokimab, a highly anticipated treatment for patients with skin disease, saw MoonLake investors' shares fall by about 90%, prompting an investigation into whether or not they were misled
Regulatory
NAD+ supplement claims under scrutiny as Niagen Bioscience wins landmark advertising case
The National Advertising Division (NAD) has ruled against Reus Research over unsupported NAD+ product claims, reinforcing that oral NAD+ ingestion lacks scientific backing and affirming Niagen’s clinically proven approach